Search Results
Staff
Abdel Elkahloun is an associate investigator in NHGRI's Office of Scientific Core Facilities.
… to defining exosomes or EVs (extra-cellular vesicles) in cancer. In 2014, and in collaboration with Dr. Roberts at … NCI, Dr. Elkahloun demonstrated that exosomes derived from cancer cells can affect the transcriptomes of surrounding … identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes. PLoS Genet, 20(11). …
Genetic Disorders
The porphyrias are a group of different diseases, each caused by a specific abnormality in the heme production process.
… estrogens (such as those used in oral contraceptives and prostate cancer treatment), and possibly smoking, combine to cause an …
Clinical Research
The CLINSEQ® Study seeks to learn about the role that your genes play in your health.
… a variety of conditions, including heart disease, breast cancer, and hearing loss. … Preliminary validation of a consumer-oriented colorectal cancer risk assessment tool compatible with the US Surgeon …
News Release
Six new grants will support researchers for new computational approaches to search millions of genomic variants for disease susceptibility.
… Human Genome Research Institute (NHGRI) and the National Cancer Institute, both parts of NIH. … can lead to diseases in people, including an inherited eye cancer, retinoblastoma. They would like to develop … University of California, San Diego/Ludwig Institute for Cancer Research; $2.3 million, three years Principal …
Genomics and Medicine
Starting in 2019, the American Journal of Human Genetics has published an annual feature identifying ten key advances in applying genomic information to clinical care that were reported in the previous 12 months of published literature. The Genomic Medicine Working Group has authored these reviews, based on its broader effort to identify notable accomplishments in genomic medicine on a monthly basis. From this larger set of published accomplishments, the working group has continued to select ten papers annually to be highlighted as the most significant.
… with gene editing 7. Validation of a clinical breast cancer risk assessment tool for all ancestries 8. Broader … with rare diseases 9. Benefits for children with suspected cancer from routine whole-genome sequencing 10. Clinical … Population screening for hereditary breast and ovarian cancer is cost effective Australian implementation of …
Event
On October 25-29, 2022, the National Human Genome Research Institute (NHGRI) will participate in the ASHG Annual Meeting - the world's largest human genetics and genomics meeting and exposition.
… Center, South Exhibit Hall 3:00 p.m. — 4:45 p.m. Cancer Germline sequencing of DNA damage repair genes in two hereditary prostate cancer cohorts reveals rare risk-associated Board No. PB1123 …
MINC
Contributors to the MINC toolkit
… Kathleen Calzone, Ph.D., R.N., AGN-BC, FAAN National Cancer Institute Donna Chase, M.S., R.N. South Shore Hospital … Cathy Glennon, R.N., MHS, OCN, NE-BC University of Kansas Cancer Center Beth Harkness, R.N., BSN, CPN Children’s … Hospital Barbara Tofani, R.N., MSN Hunterdon Regional Cancer Center …
The Genomics Landscape
In the October 2023 edition of The Genomics Landscape, NHGRI Director Eric Green, reflects on the twelve years of groundbreaking research by the Clinical Sequencing Evidence-generating Research (CSER) consortium.
… underlie top genetic risk loci for glaucoma and colorectal cancer Mukamel et al. Cell 2023 Aug 17; 186(17): 3659-3673 … a larger influence on the risk for glaucoma and colorectal cancer, respectively, compared to previously identified … program, began when NHGRI partnered with the National Cancer Institute (NCI) to fund six research sites to ease the …
File
… The Cancer Genome Atlas: A Decade of Discovery Carolyn M. Hutter, … Council on Human Genome Research September 11, 2017 2 The Cancer Genome Atlas (TCGA) Mission: A comprehensive and … to accelerate the understanding of the molecular basis of cancer through the application of genome analysis …
File
… The National Cancer Institute: Leading Cancer Research in 2021 and Beyond …